These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 31735523)

  • 41. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
    Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
    Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
    Yamaguchi O; Kaira K; Mouri A; Shiono A; Hashimoto K; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Cancer Chemother Pharmacol; 2019 May; 83(5):817-825. PubMed ID: 30758646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
    Janjigian YY; Smit EF; Groen HJ; Horn L; Gettinger S; Camidge DR; Riely GJ; Wang B; Fu Y; Chand VK; Miller VA; Pao W
    Cancer Discov; 2014 Sep; 4(9):1036-45. PubMed ID: 25074459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
    Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.
    Ng WW; Lin CC; Cheng CY; Jiang JS; Kao SJ; Yeh DY
    PLoS One; 2021; 16(6):e0253335. PubMed ID: 34166400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
    Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
    Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
    Schuler M; Fischer JR; Grohé C; Gütz S; Thomas M; Kimmich M; Schneider CP; Laack E; Märten A;
    Oncologist; 2014 Oct; 19(10):1100-9. PubMed ID: 25232040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis.
    Li D; Li M; Li H; Shi P; Chen M; Yang T
    Dis Markers; 2023; 2023():5272125. PubMed ID: 37077340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
    Chang HC; Wang CC; Tseng CC; Huang KT; Chen YM; Chang YP; Lai CH; Fang WF; Lin MC; Chuang HY
    Thorac Cancer; 2023 Nov; 14(32):3208-3216. PubMed ID: 37737541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
    Popat S; Mok T; Yang JC; Wu YL; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L
    Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
    Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
    Chang HC; Huang KT; Tseng CC; Chen YM; Lai CH; Chang YP; Chen YC; Chuang HY; Wang CC
    Thorac Cancer; 2023 Nov; 14(32):3217-3225. PubMed ID: 37704454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC.
    Ju JS; Huang AC; Tung PH; Huang CH; Chiu TH; Wang CC; Ko HW; Chung FT; Hsu PC; Fang YF; Guo YK; Kuo CS; Yang CT
    Sci Rep; 2023 Nov; 13(1):20323. PubMed ID: 37989860
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
    Zeng L; Xiao L; Jiang W; Yang H; Hu D; Xia C; Li Y; Zhou C; Xiong Y; Liu L; Liao D; Guan R; Li K; Wang J; Zhang Y; Yang N; Mansfield AS
    Lung Cancer; 2020 Mar; 141():82-88. PubMed ID: 31982639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
    Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
    Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.